VISTA antagonist and methods of use

Patent metadata

Field	Value
Publication number	US-10933115-B2
Application number	US-201515111550-A
Country	US
Kind code	B2
Filing date	Jan 23, 2015
Priority date	Jun 22, 2012
Publication date	Mar 2, 2021
Grant date	Mar 2, 2021

Abstract

The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.

First claim

What is claimed is:

1. A method for blocking, inhibiting or neutralizing VISTA-mediated T cell suppression, comprising administering to a subject an effective amount of an isolated VISTA antagonist comprising a peptide which is identical to the amino acid sequence of SEQ ID NO:1 (Ser-Ser-Ala-Cys-Asp-Trp-Ile-Lys-Arg-Ser-Cys-His), or a conjugate, thereof.

2. A method for stimulating an immune response in a subject, comprising administering to the subject an effective amount of an isolated VISTA antagonist comprising a peptide which is identical to the amino acid sequence of SEQ ID NO:1 (Ser-Ser-Ala-Cys-Asp-Trp-Ile-Lys-Arg-Ser-Cys-His), or a conjugate thereof.

3. The method of claim 2 , wherein the subject has an infectious condition or cancer.

4. A method for enhancing anti-cancer or anti-tumor immunity, comprising administering to a subject an effective amount of an isolated VISTA antagonist comprising a peptide which is identical to the amino acid sequence of SEQ ID NO:1 (Ser-Ser-Ala-Cys-Asp-Trp-Ile-Lys-Arg-Ser-Cys-His), or conjugate thereof.

5. A method for treating or inhibiting tumor invasion and/or cancer metastasis, comprising administering to a subject an effective amount of an isolated VISTA antagonist comprising a peptide which is identical to the amino acid sequence of SEQ ID NO:1 (Ser-Ser-Ala-Cys-Asp-Trp-Ile-Lys-Arg-Ser-Cys-His), or a multimer or conjugate thereof.

6. A method according to claim 5 , further comprising the administration of another therapeutic agent, wherein said peptide and therapeutic may be separately or jointly administered, at the same or different times.

Assignees

• King S College London
• Dartmouth College
• Kings Gollege London

Inventors

• Noelle Randolph J
• Ceeraz Sabrina
• Lemercier Isabelle
• Nowak Elizabeth
• Lines Janet
• Wang Li
• Spaller Mark

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/74

  Inducing cell proliferation · CPC title

• C07K16/2827

  against B7 molecules, e.g. CD80, CD86 · CPC title

• A61K38/10 Primary

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title